Advances in the relationship between AP-1 and tumorigenesis, development and therapy resistance.

IF 2.8 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Discover. Oncology Pub Date : 2025-01-20 DOI:10.1007/s12672-025-01783-1
Xinni Xue, Zhiwei Li, Jiahui Zhao, Ziyi Zhao, Zhihang Li, Yong Li, Yawen Liu, Huan He
{"title":"Advances in the relationship between AP-1 and tumorigenesis, development and therapy resistance.","authors":"Xinni Xue, Zhiwei Li, Jiahui Zhao, Ziyi Zhao, Zhihang Li, Yong Li, Yawen Liu, Huan He","doi":"10.1007/s12672-025-01783-1","DOIUrl":null,"url":null,"abstract":"<p><p>Activating protein 1 (AP-1) is a transcription factor composed of several protein families, Jun proteins and Fos proteins are the components of AP-1. AP-1 is involved in various cellular processes, such as proliferation, differentiation, apoptosis and inflammation. For tumor cells, AP-1 is considered to be a driver whose activity is associated with dysfunction and the onset, development, invasion, and migration of cancer. In addition, AP-1 has been reported to be involved in the drug resistance and radiation resistance of tumor cells during the treatment process. Therefore, AP-1 is a potential target for cancer therapy. At present, a number of inhibitors targeting AP-1 have been developed and have shown certain anti-cancer effects. However, due to the complex structure and function of AP-1, different structures of AP-1 show different effects in different tumor cells, and more studies are needed to reveal its mechanism of action. This article introduces the relationship between AP-1 and tumor development, summarize the current studies and developments of AP-1 related drugs, and provide the future development values of AP-1.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"61"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11747019/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-01783-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Activating protein 1 (AP-1) is a transcription factor composed of several protein families, Jun proteins and Fos proteins are the components of AP-1. AP-1 is involved in various cellular processes, such as proliferation, differentiation, apoptosis and inflammation. For tumor cells, AP-1 is considered to be a driver whose activity is associated with dysfunction and the onset, development, invasion, and migration of cancer. In addition, AP-1 has been reported to be involved in the drug resistance and radiation resistance of tumor cells during the treatment process. Therefore, AP-1 is a potential target for cancer therapy. At present, a number of inhibitors targeting AP-1 have been developed and have shown certain anti-cancer effects. However, due to the complex structure and function of AP-1, different structures of AP-1 show different effects in different tumor cells, and more studies are needed to reveal its mechanism of action. This article introduces the relationship between AP-1 and tumor development, summarize the current studies and developments of AP-1 related drugs, and provide the future development values of AP-1.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
AP-1与肿瘤发生、发展及耐药关系的研究进展。
激活蛋白1 (activated protein 1, AP-1)是由多个蛋白家族组成的转录因子,Jun蛋白和Fos蛋白是AP-1的组分。AP-1参与多种细胞过程,如增殖、分化、凋亡和炎症。对于肿瘤细胞,AP-1被认为是一种驱动因子,其活性与功能障碍以及癌症的发生、发展、侵袭和迁移有关。此外,有报道称AP-1在治疗过程中参与了肿瘤细胞的耐药和耐辐射。因此,AP-1是癌症治疗的潜在靶点。目前已开发出许多靶向AP-1的抑制剂,并显示出一定的抗癌作用。但由于AP-1结构和功能复杂,不同结构的AP-1在不同肿瘤细胞中的作用也不同,其作用机制有待进一步研究。本文介绍了AP-1与肿瘤发展的关系,综述了AP-1相关药物的研究进展,并提出了AP-1未来的开发价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Discover. Oncology
Discover. Oncology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
2.40
自引率
9.10%
发文量
122
审稿时长
5 weeks
期刊最新文献
Prognostic value of FCER1G expression and M2 macrophage infiltration in esophageal squamous cell carcinoma. Development of a prognostic model based on four genes related to exhausted CD8+ T cell in triple-negative breast cancer patients: a comprehensive analysis integrating scRNA-seq and bulk RNA-seq. Unraveling the heterogeneity of WHO grade 4 gliomas: insights from clinical, imaging, and molecular characterization. Relationship between programmed cell death and targeted therapy for thyroid cancer in patients with a poor prognosis: an update. Analysing DNA methylation and transcriptomic signatures to predict prostate cancer recurrence risk.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1